A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
Clinical trial NCT05984602 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05984602
- Sponsor
- NYU Langone Health
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-14
- Primary completion
- 2025-09-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.